Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA warns Mountain Meadow Herbs

This article was originally published in The Tan Sheet

Executive Summary

FDA makes good on its promise to follow up on enforcement actions by sending a warning letter to Mountain Meadow Herbs after the firm inadequately corrected problems identified during an inspection. In a Sept. 21 letter, the agency warns the Kalispell, Mont., supplement firm to revise claims that make its supplements Natural Attention-Aid, Winter-Immune Booster, Herbal Respiratory and othersunapproved new drugs. The letter follows several notices the agency sent the firm after it inspected its manufacturing facility and notified it of similar concerns. Mountain Meadow Herbs revised its claims in response to the first notice, but the changes did not satisfy FDA. Commissioner Margaret Hamburg said Aug. 6 the agency will follow up on warning letters and other enforcement actions. FDA also set a firm 15-day post-inspection deadline for firms to respond to inspections (1"The Tan Sheet" Aug. 10, 2009)

You may also be interested in...

FDA Enforcement Follow-Through Could Thin Out Violators

FDA's emphasis on follow-through in its revamped enforcement strategy may help weed out bad actors from legitimate industry

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts